Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung CancerAlice T. Shaw, Pasi A. Jänne, Dong‐Wan Kim et al.|New England Journal of Medicine|2013Cited by 3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung CancerBenjamin Solomon, Fiona Blackhall, Tony Mok et al.|New England Journal of Medicine|2014Cited by 3.2k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialWinette T.A. van der Graaf, Peter Hohenberger, Axel Le Cesne et al.|The Lancet|2012Cited by 2.1k
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trialKeunchil Park, Luis Paz‐Ares, Eng-Huat Tan et al.|The Lancet Oncology|2016Cited by 1.2k
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Patrick A. Ott, Sarina A. Piha‐Paul et al.|Journal of Thoracic Oncology|2019Cited by 437